Stay updated with breaking news from Cingulate Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cingulate Announces Successful Transfer of CTx-1301 Proprietary PTR™ Manufacturing Processes to Societal CDMO Scalable Supply of CTx-1301 Ready to be... | May 3, 2023
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities...
KANSAS CITY, Kan., April 14, 2023 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a... | April 14, 2023
KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Inc. (NASDAQ:CING – Get Rating) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 404,000 shares, a drop of 62.2% from the February 28th total of 1,070,000 shares. Based on an average daily volume of 848,400 shares, the days-to-cover ratio is currently […]